The World Health Organization (WHO) published its first guideline for Ebola virus disease (EVD) therapeutics following a systematic review and meta-analysis of randomized clinical trials, with strong recommendations for using two monoclonal antibodies, Ebanga and Inmazeb.
The WHO stated on August 19, 2022, that EVD is a severe and too often fatal illness caused by the Ebola virus and called on the global community to increase access to these lifesaving monoclonal antibodies (mAbs) treatments.
Read More